Stryker is a medical technology company that specializes in orthopedics and neurotechnology. Analyst Paige Meyer says Stryker's Mako robotic orthopedic product and its high exposure to outpatient procedures makes the stock a compelling long-term health care investment. In addition, the chronic, progressive nature of the conditions targeted by Stryker's orthopedic business will support durable procedure volume demand. Meyer says Stryker's Wright Medical Group acquisition boosts the company's presence in extremities procedures, and Stryker is making impressive progress in developing its Mako spine and shoulder applications. CFRA has a "buy" rating and $424 price target for SYK stock, which closed at $390.97 on Dec. 3.